📣 VC round data is live. Check it out!

CytoSorbents Valuation Multiples

Discover revenue and EBITDA valuation multiples for CytoSorbents and similar public comparables like Spirit Scientific Co, Polyrizon, CS Diagnostics, Pulsenmore and more.

CytoSorbents Overview

About CytoSorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.


Founded

2014

HQ

United States

Employees

149

Financials (LTM)

Revenue: $38M
Net Income: ($9M)

EV

$53M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CytoSorbents Financials

CytoSorbents reported last 12-month revenue of $38M.

In the same LTM period, CytoSorbents generated $27M in gross profit and had net loss of ($9M).

Revenue (LTM)


CytoSorbents P&L

In the most recent fiscal year, CytoSorbents reported revenue of $37M and EBITDA of ($4M).

CytoSorbents is unprofitable as of last fiscal year, with gross margin of 71%, EBITDA margin of (12%), and net margin of (22%).

See analyst estimates for CytoSorbents
LTMLast FY202320242025202620272028
Revenue$38M$37M$31M$36M$37M
Gross Profit$27M$26M$17M$25M$26M
Gross Margin71%71%55%71%71%
EBITDA($4M)($29M)($19M)($4M)
EBITDA Margin(12%)(94%)(54%)(12%)
EBIT Margin(32%)(38%)(100%)(47%)(38%)
Net Profit($9M)($8M)($29M)($21M)($8M)
Net Margin(24%)(22%)(92%)(58%)(22%)
Net Debt$10M

Financial data powered by Morningstar, Inc.

CytoSorbents Stock Performance

CytoSorbents has current market cap of $29M, and enterprise value of $53M.

Market Cap Evolution


CytoSorbents' stock price is $0.46.

CytoSorbents share price decreased by 25.0% in the last 30 days, and by 45.1% in the last year.

CytoSorbents has an EPS (earnings per share) of $-0.13.

See more trading valuation data for CytoSorbents
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$53M$29M0.0%-25.0%-38.8%-45.1%$-0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CytoSorbents Valuation Multiples

CytoSorbents trades at 1.4x EV/Revenue multiple, and (12.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for CytoSorbents

EV / Revenue (LTM)


CytoSorbents Financial Valuation Multiples

As of May 26, 2026, CytoSorbents has market cap of $29M and EV of $53M.

CytoSorbents has a P/E ratio of (3.2x).

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.4x1.7x1.5x1.4x
EV/EBITDA(12.3x)(1.8x)(2.8x)(12.3x)
EV/EBIT(4.4x)(3.8x)(1.7x)(3.2x)(3.8x)
EV/Gross Profit2.0x2.0x3.1x2.1x2.0x
P/E(3.2x)(3.5x)(1.0x)(1.4x)(3.5x)
EV/FCF(4.1x)(2.4x)(3.5x)(4.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CytoSorbents Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CytoSorbents Margins & Growth Rates

CytoSorbents grew revenue by 6% and net profit by 30% in the last fiscal year.

In the most recent fiscal year, CytoSorbents reported gross margin of 71%, EBITDA margin of (12%), and net margin of (22%).

See estimated margins and future growth rates for CytoSorbents

CytoSorbents Margins

Last FY202420252026202720282029
Gross Margin71%71%71%70%
EBITDA Margin(12%)(54%)(12%)
EBIT Margin(38%)(47%)(38%)(22%)
Net Margin(22%)(58%)(22%)(27%)
FCF Margin(35%)(42%)(35%)

CytoSorbents Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%15%4%6%
Gross Profit Growth4%47%5%4%
EBITDA Growth(34%)(77%)
EBIT Growth(40%)(46%)(15%)(40%)
Net Profit Growth30%(27%)(60%)30%
FCF Growth(33%)(15%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CytoSorbents Operational KPIs

CytoSorbents' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for CytoSorbents
LTMLast FY202320242025202620272028
Revenue per Employee$0.2M
Opex per Employee$0.3M
G&A Expenses to Revenue122%
R&D Expenses to Revenue12%14%51%19%14%
Opex to Revenue110%155%118%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CytoSorbents Competitors

CytoSorbents competitors include Spirit Scientific Co, Polyrizon, CS Diagnostics, Pulsenmore, IMD International Medical, Genematrix, Implanet, Vivos, NeuroOne Medical and Trajan Group Holdings.

Most CytoSorbents public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Spirit Scientific Co2.3x11.3x
Polyrizon(5.3x)
CS Diagnostics
Pulsenmore0.3x(0.9x)
IMD International Medical0.4x5.8x
Genematrix2.7x(24.7x)
Implanet2.4x(8.1x)
Vivos

This data is available for Pro users. Sign up to see all CytoSorbents competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CytoSorbents

When was CytoSorbents founded?CytoSorbents was founded in 2014.
Where is CytoSorbents headquartered?CytoSorbents is headquartered in United States.
How many employees does CytoSorbents have?As of today, CytoSorbents has over 149 employees.
Who is the CEO of CytoSorbents?CytoSorbents' CEO is Phillip P. Chan.
Is CytoSorbents publicly listed?Yes, CytoSorbents is a public company listed on Nasdaq.
What is the stock symbol of CytoSorbents?CytoSorbents trades under CTSO ticker.
When did CytoSorbents go public?CytoSorbents went public in 2005.
Who are competitors of CytoSorbents?CytoSorbents main competitors include Spirit Scientific Co, Polyrizon, CS Diagnostics, Pulsenmore, IMD International Medical, Genematrix, Implanet, Vivos, NeuroOne Medical, Trajan Group Holdings.
What is the current market cap of CytoSorbents?CytoSorbents' current market cap is $29M.
What is the current revenue of CytoSorbents?CytoSorbents' last 12 months revenue is $38M.
What is the current revenue growth of CytoSorbents?CytoSorbents revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of CytoSorbents?Current revenue multiple of CytoSorbents is 1.4x.
Is CytoSorbents profitable?No, CytoSorbents is not profitable.
What is the current net income of CytoSorbents?CytoSorbents' last 12 months net income is ($9M).
How many companies CytoSorbents has acquired to date?CytoSorbents hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CytoSorbents has invested to date?CytoSorbents hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CytoSorbents

Lists including CytoSorbents

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial